FindTrial
Sign In

Evaluation of an immune-related blood protein (HLA-B27) in migraine patients and healthy people

Evaluation of HLA-B27 marker in peripheral blood of migraine patients: A case-control study - Nil

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2026/01/101626
Enrollment
51
Registered
2026-01-20
Start date
Unknown
Completion date
Unknown
Last updated
2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G439- Migraine, unspecified

Interventions

Control Intervention1: Nil: Nil

Sponsors

Nil
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Migraine with aura (MWA) and Migraine without aura (MWOA) patients 2.Patients above 18 years old 3.Confirmation of migraine by a neurologist

Exclusion criteria

Exclusion criteria: 1.Patients with additional comorbidity conditions were not allowed to participate. 2.Patients who have recently taken any immunosuppressants 3.Pregnant women were excluded 4.Patients with previous head injury

Design outcomes

Primary

MeasureTime frame
The outcome of the study will provide prevalence of HLA-B27 positivity in migraine patients compared to healthy participantTimepoint: Blood samples will be collected at a single, predefined time point during the pain-free (interictal) phase.—

Secondary

MeasureTime frame
Explore potential differences between migraine subtypes( migraine with aura & without aura)Timepoint: Blood samples will be collected at a single, predefined time point during the pain-free (interictal) phase.—

Countries

India

Contacts

Public ContactSowmiya M

Sri Ramachandra Institute of Higher Education and Research

murugesan.a@sriramachandra.edu.in8870151588

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 7, 2026